The meteoric rise of GLP-1 medications like semaglutide and tirzepatide for weight management has created an unexpected clinical dilemma: these powerful appetite suppressants may inadvertently trigger or worsen eating disorders in vulnerable populations. This emerging concern challenges the widespread enthusiasm surrounding these breakthrough obesity treatments.
The medications work by mimicking incretin hormones that regulate blood sugar and slow gastric emptying, leading to profound appetite reduction and significant weight loss. However, this mechanism may prove problematic for individuals with histories of restrictive eating patterns, binge eating disorder, or body dysmorphia. The drugs' ability to dramatically reduce food intake could potentially reinforce unhealthy relationships with food or provide a medical avenue for those seeking extreme weight control.
This intersection of metabolic medicine and psychiatric health represents uncharted territory in obesity treatment. While GLP-1 agonists have demonstrated remarkable efficacy in clinical trials, those studies typically excluded participants with active eating disorders, leaving critical safety questions unanswered. The concern extends beyond individual patient risk to broader societal implications, as these medications become increasingly accessible and culturally normalized as weight management tools.
The clinical challenge lies in distinguishing therapeutic appetite regulation from pathological food restriction. Healthcare providers must now navigate screening for eating disorder risk while prescribing these medications, particularly given the overlap between obesity and disordered eating behaviors. This emerging evidence suggests the need for enhanced psychiatric screening protocols and potentially collaborative care models involving both endocrinologists and eating disorder specialists when prescribing GLP-1 therapies.